Behandling af neuroendokrine gastrointestinale tumorer

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Behandling af neuroendokrine gastrointestinale tumorer. / Hansen, Carsten Palnaes; Langer, Seppo; Frevert, Susanne; Mortensen, Jann; Kjaer, Andreas; Knigge, Ulrich.

I: Ugeskrift for Laeger, Bind 172, Nr. 43, 25.10.2010, s. 2942-5.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hansen, CP, Langer, S, Frevert, S, Mortensen, J, Kjaer, A & Knigge, U 2010, 'Behandling af neuroendokrine gastrointestinale tumorer', Ugeskrift for Laeger, bind 172, nr. 43, s. 2942-5.

APA

Hansen, C. P., Langer, S., Frevert, S., Mortensen, J., Kjaer, A., & Knigge, U. (2010). Behandling af neuroendokrine gastrointestinale tumorer. Ugeskrift for Laeger, 172(43), 2942-5.

Vancouver

Hansen CP, Langer S, Frevert S, Mortensen J, Kjaer A, Knigge U. Behandling af neuroendokrine gastrointestinale tumorer. Ugeskrift for Laeger. 2010 okt. 25;172(43):2942-5.

Author

Hansen, Carsten Palnaes ; Langer, Seppo ; Frevert, Susanne ; Mortensen, Jann ; Kjaer, Andreas ; Knigge, Ulrich. / Behandling af neuroendokrine gastrointestinale tumorer. I: Ugeskrift for Laeger. 2010 ; Bind 172, Nr. 43. s. 2942-5.

Bibtex

@article{267c0e6563ee493e82c9d7bd98c0f32b,
title = "Behandling af neuroendokrine gastrointestinale tumorer",
abstract = "The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.",
keywords = "Antineoplastic Agents/therapeutic use, Combined Modality Therapy, Gastrointestinal Neoplasms/drug therapy, Humans, Liver Neoplasms/secondary, Neuroendocrine Tumors/drug therapy, Palliative Care, Pancreatic Neoplasms/drug therapy, Practice Guidelines as Topic, Prognosis",
author = "Hansen, {Carsten Palnaes} and Seppo Langer and Susanne Frevert and Jann Mortensen and Andreas Kjaer and Ulrich Knigge",
year = "2010",
month = oct,
day = "25",
language = "Dansk",
volume = "172",
pages = "2942--5",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "43",

}

RIS

TY - JOUR

T1 - Behandling af neuroendokrine gastrointestinale tumorer

AU - Hansen, Carsten Palnaes

AU - Langer, Seppo

AU - Frevert, Susanne

AU - Mortensen, Jann

AU - Kjaer, Andreas

AU - Knigge, Ulrich

PY - 2010/10/25

Y1 - 2010/10/25

N2 - The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.

AB - The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.

KW - Antineoplastic Agents/therapeutic use

KW - Combined Modality Therapy

KW - Gastrointestinal Neoplasms/drug therapy

KW - Humans

KW - Liver Neoplasms/secondary

KW - Neuroendocrine Tumors/drug therapy

KW - Palliative Care

KW - Pancreatic Neoplasms/drug therapy

KW - Practice Guidelines as Topic

KW - Prognosis

M3 - Tidsskriftartikel

C2 - 21040671

VL - 172

SP - 2942

EP - 2945

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 43

ER -

ID: 248232102